6^th International Conference on Biomarkers & Clinical Research September 01-02, 2015 Toronto, Canada

Team Biomarkers continues it's conference series to up its 6^th chapter - Biomarkers conference 2015 and call upon the scientific community to attend biomarker meeting to take the biomolecular signature set to a probable therapeutic discovery in Toronto, Canada from August 31-September 02, 2015 at 6^th International Conference on Biomarkers and Clinical Research. Biomarkers-2015 follows the theme “Lab to Industry as Biosignatures to Therapeutic Discovery”. OMICS International Organizes 300+ conferences, 500+workshops and 200+symposiums on Clinical, Medicine, Pharma and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Biomarkers Conference 2015 aims to put forth a global platform to share experience, knowledge, enlighten young aspiring minds on the latest advancements in the field of Biomarkers and to deliver novel ideas besides incorporating better understanding of the disease diagnosis, prognosis and therapeutic intervention. Biomarkers conferences  intends to ground experts from across the globe inclusive of scientific eminent personnel, doctors, clinicians, young researchers and corporate leaders from diverse disciplines emphasizing the areas of types & approaches for biomarker discovery, biomarkers in data analysis, clinical research & development, molecular dynamics, biomarkers of exposure, response, disorders.

Biomarker congress will enable to put forth the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis. Biomarker conference exhilarating scientific program will focus on Types of Biomarkers, Cancer Biomarkers, Functional Genomics and Cytogenetic Biomarkers, Biomarkers in clinical research and development, Biomarkers for Disorders along with Technologies to maximize Biomarker identification. Biomarkers congress will be platform for business delegates, B2B meetings, poster presentations, Biomarkers workshops, biomarkers symposia and much more. The past five conference series of biomarkers meeting have grounded the best possible researchers in the field of biomarkers from diverse scientific disciplines, and so will be the upcoming.

Total market value of Biomarkers in 2014 is $5.95 Billion and it is expected to reach $30 Billion in 2020 growing at CAGR of 16% from 2014 to 2020. Biomarkers major verticals are usually supplied by market of application and market of services. Common Annual Growth Rate of more than 37% is gained by market for application and Common Annual Growth Rate of more than 39% are gained from the market of services. Thus the common annual growth is 49% by revenue. Nowadays scope of biomarkers has a vital role in efficacy of the therapeutic process all around the world. Establishing the standardization of drug development has a major role for the development of disease pathway. Also, Research portfolio of biomarkers discovery has an application in all the major scientific studies.

For more information, please visit: Biomarkers Analysis Report

Types of Biomarkers

Biomarker is a characteristic diagnostic tool that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. Biomarkers can be molecules, or genes, gene products, enzymes, or hormones referred as protein biomarkers, analytical biomarkers, blood biomarkers, fluorescent biomarkers, circulating biomarkers and molecular biomarkers to quantify the degree of disease condition. Biomarkers are the measures used to perform a clinical assessment in case of cancer biomarkers. They predict health states in individuals across populations so that appropriate therapeutic intervention can be planned. In the current scenario more than a thousand organizations and universities have contributed to the field of Biomarkers research especially molecular and cancer biomarkers, with its wings spreading across major organizations in USA, UK, Germany and China. The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.

Functional Genomics and Cytogenetic Biomarkers

The branch of genomics that determines the biological function and complex association of the genes and their products depicts the functional genomics. The measurable degree of these parameters through various processes and equipment inclusive of Next generation sequencing, Personalized genome sequencing and mi-RNA sequencing utilizing cellular entities to predict SNP biomarkers, immunofluorescent biomarkers, oxidative stress biomarkers, si-RNA and mi-RNA will aid in better understanding of the disease outcome. The cytogenetic biomarkers are a feasible diagnostic tool to detect DNA and chromatin damage. The newly emerged discipline in the field of cytogenetic and functional genomics is Molecular imaging biomarkers, aids in better visualization of the cellular function and the follow-up of the molecular process in living organisms without penetrance. Roche Diagnostics, GlaxoSmithKline, Siemens Healthcare, GE Healthcare and Merck & Co are a few of the key players in this market as observed in biomarkers congress. The functional genomics and cytogenetic market is estimated to reach 150M$ by 2017.

Biomarkers in Clinical Research and Development

The Biomarkers finds its valuable application in the field of Clinical research and development by case study and data management as evident through Biomarker conferences. The Bioethics and intellectual property right establishes the norms and standard of conduct of hypothesis with respect to clinical validation of biomarkers. The incorporation of biomarker in clinical trials for various disease conditions will put forth a valid diagnostic and therapeutic approach utilizing even the medical devices to detect clinical biomarkers. Currently this is the booming industry. Most of the reputed organizations like Pfizer, Parexel and Quintiles are into clinical research and development. The companies, hospitals and clinical research organizations are the hot spots for conducting clinical research with its growth rate increasing exponentially by an estimated  75B$ by 2016.

Omics Technologies in Biomarkers Discovery and Validation

Biomarkers play a critical role in disease diagnosis and treatment, especially for the early detection of cancer, to enable screening of asymptomatic populations. Recent omics technologies, such as transcriptomics, genomics and proteomics approaches besides Metabonomics are accelerating the rate of biomarker discovery. The incorporation of techniques like microarray data analysis, computational biology, data mining methods, transcriptomics and profiling techniques are playing a crucial role in the validation of biomarkers. Since the Human Genome Project was completed in April 2003, genome-wide association studies (GWAS) have contributed toward a greater understanding of the genetic basis of complex diseases and advances in high-throughput technologies. This has enabled researchers to rapidly map the genome of vertebrates, invertebrates and pathogens through cost-effective methods. The applications of Bioinformatics tool in biomarker research is the current emerging field promoting better diagnosable parameters. The global omics market was valued at nearly $2.8 billion in 2011, nearly $3.2 billion in 2012, and is forecast to grow to nearly $7.5 billion by 2017 after increasing at a compound annual growth rate (CAGR) of 18.7%. The omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally.

Biomarkers of Exposure Response and Susceptibility

Biomarkers of exposure are important in toxicology, because they are an indicator of internal exposure and genetic susceptibility to drug, chemicals or the amount of chemical exposure that got accumulated in the body. Significant advances have been made in developing analytical methods that detect and quantify many natural or synthetic toxins or their breakdown products in the biological matrix. The ability to accurately measure biomarkers of exposure depends upon an adequate understanding of the chemistry and toxicology of the substance under consideration. Epigenetic biomarkers also quantify the degree of exposure to toxicodynamic and pharmacodynamics parameters in pathological and biochemical changes occurring due to exposure to harmful agents, brought to light by toxicodynamics meetings and pharmacodynamics workshops. This emerging field of study is gaining importance in industry with an estimate of more than 7,287 personnel conducting study across the globe.

Biomarkers for Disorders

Biomarkers are the characteristic biological measurable indictors for the various disorders if occurring in abnormal levels. These are used as quantitative entities for neurological disorders, genetic disorders, metabolic disorders, cardiac disorders and inborn errors. The present era is focusing on the cancer research utilizing biomarkers as indictor of disease conditions. The lung cancer biomarkers and biomarkers for breast cancer are inclusive of genes, enzymes, proteins and cell surface entitles. Registering a compound annual growth rate of 14.60% from 2011 to 2018, the market for oncology biomarkers was valued at $13.16 billion in 2011 and is expected to be worth $29.78 billion in 2018.

Techniques to Maximize Biomarker Identification

Biomarkers are the existing biomolecular and integral indictors of disease condition of biological systems. The techniques used to identify and maximize the expression of biomarkers include RT-PCR genotyping, molecular imaging and dynamics, biochemical assay and profiling, immunological techniques and chromatographic techniques. A wider approach towards identification of biomarkers lies in the proteomic approach besides utilizing biosensors as a compatible tool for evaluation of biomarker levels in the biological systems. Most of the companies focus on generating cost effective durable profiling techniques and equipment to quantify biomarkers within a short span of time. Johnson & Johnson, GlaxoSmithKline Plc., GE Healthcare, Affymetrix Inc., Bio-Rad Laboratories Inc. are a few of the key players in this market. Partnerships, agreements, collaborations, & mergers and acquisitions are the key business strategies adopted by market participants to ensure their growth in the market.

Biomarkers in Nano science

Nanoscience is the study of structures and materials on the scale of nanometers. Nanotechnology may be able to create many new materials and devices with a vast range of applications in medicine, electronics, biomaterials energy production, and consumer products. Nanotechnology is evolving rapidly with nanoparticles events.  An estimated 1 million workers in R&D and production are involved in the field of nanoscience and nanomaterial generation. Interaction of biomarkers with nanoparticles aids in identification and validation through biological and biomedical applications. Current market holds nanodevices and nanomaterial for identification, quantifying, calibrating and even in surgeries. The US leads the world in investing and in the number of Nanotech Companies. Global consumption of nanomaterial is expected to grow in unit terms from nearly 225,060 metric tons in 2014 to nearly 584,984 metric tons in 2019, a compound annual growth rate (CAGR) of 21.1% for the period of 2014 to 2019.

Biomarkers for Data Statistics

Biomarkers are important for streamlining drug discovery and development. In addition, biomarkers can be widely used as a tool for disease diagnosis, personalized medication in clinical research. Study design and statistical analysis for biomarker research incorporates various tools from bioinformatics. It further involves patient segmentation and stratification by successful integration of diagnostic tools and clinical data annotation inclusive of classification distribution metrics and pattern recognition. The global market for biomarkers in data statistics is estimated at about $2.4 billion in 2011 and further projected to reach $7.6 billion by 2017 registering a CAGR of 18.3% during the period 2007-2017. The organizations involved are Affymetrix, Agilent Technologies, Biomax Informatics, Illumina, Qiagen etc amongst others across the globe.

Biomarkers Industry & Market Analysis

With the emerging importance to quantify and validate various disease conditions, many organizations, companies, and universities have stepped forward to contribute to the field of biomarkers discovery and quantification for better prognosis of disease conditions. The Biomarkers is the second leading industry after clinical research and development. The Biomarkers in pharmaceutical industry, biomarkers in oncology & other diseases has attained utmost recognition due to global spread of cancer and other diseases. The Biomarkers validation and regulatory affairs and diagnostic biomarker are booming industry with an estimate of more than 270 companies involved across the globe in 2015.